Roche: Gantenerumab discontinued in prodromal AD, MARIANNE not as good as hoped

NEUTRAL, Fair Value CHF302 (+5%)

News published on December Friday 19, 2014
Share on

In two separate press releases, Roche today announce that (i) gantenerumab is being discontinued in prodromal Alzheimer’s disease (AD) based on the results of a pre-planned futility analysis and a recommendation by the DMC although it is moving forward in later stages of AD; (ii) the MARIANNE phase III whose primary endpoint was comparative PFS between Herceptin-based SoC, Kadcyla and Kadcyla/Perjeta delivers first data which show non-inferiority but not superiority which indeed is disappointing and could make inroads for new HER2+ therapies less easy for Roche.

For more information, please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities